User profiles for Carlo Torti
 | Carlo TortiUniversity "Magna Graecia", Catanzaro, Italy Verified email at unicz.it Cited by 16987 |
Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING …
F Raffi, A Rachlis, HJ Stellbrink, WD Hardy, C Torti… - The Lancet, 2013 - thelancet.com
Background Dolutegravir (S/GSK1349572) is a once-daily HIV integrase inhibitor with
potent antiviral activity and a favourable safety profile. We compared dolutegravir with HIV …
potent antiviral activity and a favourable safety profile. We compared dolutegravir with HIV …
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a …
…, B Masquelier, C Stephan, C Torti… - The Lancet infectious …, 2011 - thelancet.com
Background The effect of transmitted drug resistance (TDR) on first-line combination
antiretroviral therapy (cART) for HIV-1 needs further study to inform choice of optimum drug …
antiretroviral therapy (cART) for HIV-1 needs further study to inform choice of optimum drug …
[HTML][HTML] Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological …
…, A Skaletz-Rorowski, I Suarez-Lozano, C Torti… - PLoS …, 2013 - journals.plos.org
Background Few studies have monitored late presentation (LP) of HIV infection over the
European continent, including Eastern Europe. Study objectives were to explore the impact of …
European continent, including Eastern Europe. Study objectives were to explore the impact of …
All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort …
Background Using data from a large European collaborative study, we aimed to identify the
circumstances in which treated HIV-infected individuals will experience similar mortality rates …
circumstances in which treated HIV-infected individuals will experience similar mortality rates …
Natural history of chronic hepatitis B in co-infected patients
HIV co-infection influences the course and natural history of hepatitis B virus (HBV) infection
by impairing the quantity and quality of the innate and adaptive immune response. The rates …
by impairing the quantity and quality of the innate and adaptive immune response. The rates …
Early impairment of gut function and gut flora supporting a role for alteration of gastrointestinal mucosa in human immunodeficiency virus pathogenesis
Our results show that impairment of the gastrointestinal tracts in human immunodeficiency
virus (HIV)-positive patients is present in the early phases of HIV disease. This impairment is …
virus (HIV)-positive patients is present in the early phases of HIV disease. This impairment is …
Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings from the …
…, R Sgariglia, PG Simeone, E Spinoni, C Torti… - Nutrition, Metabolism …, 2020 - Elsevier
Background and aims There is poor knowledge on characteristics, comorbidities and
laboratory measures associated with risk for adverse outcomes and in-hospital mortality in …
laboratory measures associated with risk for adverse outcomes and in-hospital mortality in …
[HTML][HTML] Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: results of the “COPA” pilot randomized trial
…, B Van't Land, KB Amor, J Van Schaik, C Torti… - Mucosal …, 2011 - Elsevier
Intestinal mucosal immune system is an early target for human immunodeficiency virus type
1 (HIV-1) infection, resulting in CD4 + T-cell depletion, deterioration of gut lining, and fecal …
1 (HIV-1) infection, resulting in CD4 + T-cell depletion, deterioration of gut lining, and fecal …
[HTML][HTML] Heparin in COVID-19 patients is associated with reduced in-hospital mortality: the multicenter Italian CORIST study
…, PG Simeone, E Taddei, C Torti… - Thrombosis and …, 2021 - thieme-connect.com
Introduction A hypercoagulable condition was described in patients with coronavirus disease
2019 (COVID-19) and proposed as a possible pathogenic mechanism contributing to …
2019 (COVID-19) and proposed as a possible pathogenic mechanism contributing to …
The incidence of AIDS-defining illnesses at a current CD4 count≥ 200 cells/µL in the post–combination antiretroviral therapy era
…, JK Rockstroh, D Salmon, C Torti… - Clinical infectious …, 2013 - academic.oup.com
Background. Few studies consider the incidence of individual AIDS-defining illnesses (ADIs)
at higher CD4 counts, relevant on a population level for monitoring and resource allocation. …
at higher CD4 counts, relevant on a population level for monitoring and resource allocation. …